retatrutide triple agonist glp-1 gip glucagon phase 2 obesity From to Metabolic Health: Why Is a Game-Changer Effects, working principles and target
Description
Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial
doi: 10.1210/jc.2003-031403
A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control
PMID: 40010803
When one drug inhibits CYP enzymes responsible for metabolising another CNS drug, plasma and brain concentrations may rise, increasing the risk of toxicity
Samols, Marks
